Compare Pfizer with ALEMBIC PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ALEMBIC PHARMA - Comparison Results

PFIZER     Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER ALEMBIC PHARMA PFIZER/
ALEMBIC PHARMA
 
P/E (TTM) x 33.4 15.6 214.3% View Chart
P/BV x 5.6 3.6 156.2% View Chart
Dividend Yield % 0.6 1.1 57.3%  

Financials

 PFIZER   ALEMBIC PHARMA
EQUITY SHARE DATA
    PFIZER
Mar-18
ALEMBIC PHARMA
Mar-19
PFIZER/
ALEMBIC PHARMA
5-Yr Chart
Click to enlarge
High Rs2,365664 356.2%   
Low Rs1,625412 394.0%   
Sales per share (Unadj.) Rs430.3208.7 206.2%  
Earnings per share (Unadj.) Rs78.731.0 253.9%  
Cash flow per share (Unadj.) Rs93.237.1 251.1%  
Dividends per share (Unadj.) Rs20.005.50 363.6%  
Dividend yield (eoy) %1.01.0 98.1%  
Book value per share (Unadj.) Rs586.5144.2 406.7%  
Shares outstanding (eoy) m45.75188.52 24.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.62.6 179.8%   
Avg P/E ratio x25.317.4 146.0%  
P/CF ratio (eoy) x21.414.5 147.6%  
Price / Book Value ratio x3.43.7 91.2%  
Dividend payout %25.417.7 143.2%   
Avg Mkt Cap Rs m91,271101,461 90.0%   
No. of employees `0002.6NA-   
Total wages/salary Rs m3,1437,467 42.1%   
Avg. sales/employee Rs Th7,484.8NM-  
Avg. wages/employee Rs Th1,195.0NM-  
Avg. net profit/employee Rs Th1,369.1NM-  
INCOME DATA
Net Sales Rs m19,68539,347 50.0%  
Other income Rs m1,14394 1,218.4%   
Total revenues Rs m20,82839,441 52.8%   
Gross profit Rs m5,0038,736 57.3%  
Depreciation Rs m6631,152 57.5%   
Interest Rs m4184 2.3%   
Profit before tax Rs m5,4797,493 73.1%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-93 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,8781,568 119.8%   
Profit after tax Rs m3,6015,844 61.6%  
Gross profit margin %25.422.2 114.5%  
Effective tax rate %34.320.9 163.9%   
Net profit margin %18.314.9 123.2%  
BALANCE SHEET DATA
Current assets Rs m24,16719,577 123.4%   
Current liabilities Rs m9,54414,896 64.1%   
Net working cap to sales %74.311.9 624.4%  
Current ratio x2.51.3 192.7%  
Inventory Days Days5590 61.4%  
Debtors Days Days2945 63.3%  
Net fixed assets Rs m9,51427,097 35.1%   
Share capital Rs m458377 121.4%   
"Free" reserves Rs m26,37526,811 98.4%   
Net worth Rs m26,83227,188 98.7%   
Long term debt Rs m254,993 0.5%   
Total assets Rs m36,90047,778 77.2%  
Interest coverage x1,305.541.7 3,130.7%   
Debt to equity ratio x00.2 0.5%  
Sales to assets ratio x0.50.8 64.8%   
Return on assets %9.812.6 77.4%  
Return on equity %13.421.5 62.4%  
Return on capital %20.423.6 86.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m2219,453 0.1%   
Fx outflow Rs m1,4896,065 24.5%   
Net fx Rs m-1,46613,388 -11.0%   
CASH FLOW
From Operations Rs m3,3188,120 40.9%  
From Investments Rs m-2,383-7,556 31.5%  
From Financial Activity Rs m-1,104590 -186.9%  
Net Cashflow Rs m-1691,153 -14.6%  

Share Holding

Indian Promoters % 0.0 74.1 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 2.9 258.6%  
FIIs % 4.9 9.1 53.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 13.9 170.5%  
Shareholders   85,207 49,328 172.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   FULFORD INDIA  VENUS REMEDIES  STERLING BIOTECH  WOCKHARDT  AUROBINDO PHARMA  

Compare PFIZER With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 36.4% (Quarterly Result Update)

Aug 21, 2019 | Updated on Aug 21, 2019

For the quarter ended June 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 36.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.0% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

PFIZER Announces Quarterly Results (1QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, PFIZER has posted a net profit of Rs 1 bn (up 22.8% YoY). Sales on the other hand came in at Rs 5 bn (up 6.3% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

PFIZER Announces Quarterly Results (4QFY19); Net Profit Up 4.7% (Quarterly Result Update)

May 29, 2019 | Updated on May 29, 2019

For the quarter ended March 2019, PFIZER has posted a net profit of Rs 1 bn (up 4.7% YoY). Sales on the other hand came in at Rs 5 bn (up 3.0% YoY). Read on for a complete analysis of PFIZER's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Sep 20, 2019 (Close)

TRACK PFIZER

PFIZER - STERLING BIOTECH COMPARISON

COMPARE PFIZER WITH

MARKET STATS